<DOC>
	<DOCNO>NCT01992796</DOCNO>
	<brief_summary>The investigator propose clinical study irbersartan early treatment severe sepsis patient elevate predicted risk death . This study evaluate whether early administration angiotensin receptor blocker irbersartan provide significant reduction 28 day mortality multi organ failure incidence patient severe sepsis .</brief_summary>
	<brief_title>Angiotensin II Antagonist Severe Sepsis</brief_title>
	<detailed_description>Background : Angiotensin II ( ANG II ) potent vasoconstrictor diminishes vasodilator response artery . In addition direct effect vascular tone , ANG II affect multiple aspect microvascular function promotion leukostasis , induction capillary permeability depletion glutathione . Binding ANG II receptor ( particular AT1 ) mediate intracellular free radical generation contributes tissue damage promote mitochondrial dysfunction . Angiotensin receptor blocker ( ARBs ) interrupt renin-angiotensin system ( RAS ) overactivity block specific receptor mediate pathogenic activity angiotensin II . Objectives : The clinical question objective study antiinflammatory effect ARBs relevant sepsis management particular ARBs able improve survival reduce incidence Multi Organ Failure septic patient . Methods : STUDY DESIGN : Experimental ; prospective , randomize , multicenter , phase III trial . STUDY POPULATION : Three hundred adult within 12 hrs recognition severe sepsis , Acute Physiology Chronic Health Evaluation ( APACHE ) II-predicted risk mortality 20 % 80 % eligible . Settings : 5 Italian Intensive Care Units . Oral irbesartan ( total dose 75 mg ) placebo administer every 24 hr 15 day . Analysis data perform blind operator . Expected result : 25 % reduction 28-day mortality rate incidence multi organ failure study population .</detailed_description>
	<mesh_term>Sepsis</mesh_term>
	<mesh_term>Toxemia</mesh_term>
	<mesh_term>Irbesartan</mesh_term>
	<criteria>adult within 12 hrs recognition severe sepsis , Acute Physiology Chronic Health Evaluation ( APACHE ) IIpredicted risk mortality 20 % 80 % eligible . Patients already treat ACE inhibitor ARBs exclude . Patients admit shock condition ( systolic blood pressure low 90 mmHg ) exclude . Patients severe renal failure ( serum creatinine 2.0 mg/dL dialysis ) exclude .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2013</verification_date>
	<keyword>irbesartan , angiotensin , sepsis</keyword>
</DOC>